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THETREATMENT OF MODERATETO SEVERE PERSISTENT
ASTHMA IN SELECTED AUTONOMOUS COMMUNITIES IN
SPAIN:AN ECOMIC MODELTO ESTIMATE BUDGET IMPACT
CONSEQUENCES OF INTRODUCING BECLOMETHASONE/
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OBJECTIVES: A budget impact model (BIM) was developed to
estimate the economic impact of introducing beclomethasone/
formoterol extraﬁne for the treatment of moderate to severe
persistent asthma in most important Autonomous Communities
in Spain. METHODS: Analytic model was based on data from
disease prevalence, population growth, drug consumption, retail
prices and market shares forecasting for most representative
Autonomous Communities in Spain: Andalusia, Catalonia,
Madrid, Vasc Country and Valencia. It takes the perspective of
the Spanish National Pharmaceutical budget and time horizon
considered was 5 years (5% annual discount rate). Drugs con-
sidered in the study were ﬂuticasone/salmeterol, budesonide/
formoterol and beclomethasone/formoterol extraﬁne. The model
estimates the annual cost to treat patients with moderate to
severe persistent asthma before and after the introduction of
beclomethasone/formoterol extraﬁne. Costs are referred to year
2008. RESULTS: According to demographic forecasts and
asthma prevalence, target population with moderate to severe
persistent asthma treated with ﬁxed dose combinations would
be around 104,634 patients in year 2007 in Andalusia, 54,362
in Catalonia, 36,727 in Madrid, 16,311 the Vasc Country and
35,132 in Valencia. On average, cost per patient was estimated at
€982 before the introduction of beclomethasone/formoterol
extraﬁne on the Spanish pharmaceutical market and at €964
after its introduction. CONCLUSIONS: This study estimates
that the introduction of beclomethasone/formoterol extraﬁne for
the treatment of moderate to severe persistent asthma on differ-
ent Autonomous Communities is going to represent a net savings
in the pharmaceutical budget during the next 5 years of around
€11 million in Andalusia, €5.8 million in Catalonia, €4 million in
Madrid, €1.7 in the Vasc Country and €3.9 in Valencia.
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OBJECTIVES: Tobacco use is a signiﬁcant cause of morbidity
with consequent marked economic burden. So far, smoking ces-
sation (SC) medications are not reimbursed in Finland. We evalu-
ated the current and future costs of smoking related diseases
for society and the potential returns for investments in SC.
METHODS: We estimated minimum and maximum smoking
attributable proportions of relevant diseases from literature.
Comprehensive population based Finnish registry data was
combined to evaluate major expenditures (health care costs,
sick-leave compensations, disability pensions, and loss of pro-
ductivity) in 2006 euros from 1996 to 2006. Future expenses
were extrapolated from relevant data and the inﬂuence of SC
assessed in models with several survival patterns. Models were
ﬁtted with three SC medications with different efﬁcacies
(A = 5%, B = 10% and C = 20% success) and one-time costs
(starting from A = €100, B = €200, C = €300 per patient). Return
on investment for government provided drug administration
to 20 000 patients from 2008 to 2017 was calculated for all
options. RESULTS: In the minimum tobacco inﬂuence scenario,
total annual societal costs of smoking attributed morbidities
were €290M with health care costs of €145M (year 2006). This
scenario yielded an increase in real total costs to €376M by 2030.
Respective estimations in maximum scenario were €554M,
€280M and €717M. By subsidizing a free withdrawal drug
delivery for 10 years, the government incurred a cost of €2.3M
(A) €4.5 (B) and €6.8M (C), but received net present value (NPV)
of €29M (A), €57M (B) and €130M (C), through savings from
decreased health related expenditures (5% discount rate used).
Values in the maximum scenarios were €66M, €131M and
€227M. Tobacco tax was not included in the analysis. CON-
CLUSIONS: The costs of smoking for society are projected to
increase during the near future. Our models show that subsidy of
SC drugs is a sound investment.
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GERMANY INCLUDINGTHE EFFECTS OF RESISTANCE
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OBJECTIVES: To evaluate the cost-effectiveness of the empirical
oral moxiﬂoxacin treatment in Acute Exacerbation of Chronic
Bronchitis (AECB) including clinical failure caused by antimicro-
bial resistance in Germany. METHODS: A decision analytic
model was developed in AECB to estimate clinical success and
failure of oral antimicrobial treatment initiated in the commu-
nity. Three common pathogens, S.pneumoniae, H.inﬂuenzae, and
P.aeruginosa (and other gram-negative) were included using their
relative frequencies. Resistance rates were obtained from litera-
ture. A pooled analysis of seven randomised clinical trials
provided all clinical evidence for moxiﬂoxacin, macrolides and
beta-lactams, using results from the per-protocol population as
representative of non-resistant efﬁcacy and intent-to-treat popu-
lation in sensitivity analyses. Natural host resolution from
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placebo-controlled studies was used to model clinical success
in patients with resistant pathogens. Patients and efﬁcacy rates
were stratiﬁed by severity (mild/moderate;severe) deﬁned as the
number of acute exacerbations (3 and >3) over the last 12
months. Patients could receive up to two treatments in the com-
munity and one hospitalisation. Second-line treatment was based
on German guidelines and expert opinion. Outcomes evaluated
were clinical failure, hospitalisations and second-line treatments
avoided. Resource use and costs were obtained from the trials,
expert opinion and literature. RESULTS: Moxiﬂoxacin domi-
nated all other strategies. Clinical failure rates for moxiﬂoxacin,
beta-lactams and macrolides strategies were 13.1%, 19.1% and
25.3% respectively. Moxiﬂoxacin resulted in a 35% and 58%
reduction in hospitalisation compared with beta-lactams and
macrolides respectively. Results for macrolides and beta-lactams
are affected by lower clinical success rates and higher levels of
resistance for these treatments. Moxiﬂoxacin did not loose its
dominance in any deterministic sensitivity analysis conducted.
CONCLUSIONS: Despite very low overall resistance levels in
Germany, moxiﬂoxacin as ﬁrst line treatment in AECB is a cost-
saving treatment strategy. Even larger economic and clinical
beneﬁts can be expected in countries with higher prevailing resis-
tance rates.
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COST-EFFECTIVENESS OF INCREASING MAINTENANCE
DOSES WITH BUDESONIDE/FORMOTEROL
MAINTENANCE + RELIEVERTHERAPY
Kuna P1,Aubier M2, Buhl R3
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2Hôpital Bichat Claude Bernard, Paris, France, 3Mainz University
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OBJECTIVES: Budesonide/formoterol (B/F; Symbicort®) mainte-
nance and reliever therapy (SMART) provides superior exacer-
bation control to higher ﬁxed-dose ICS/LABA + SABA at a lower
cost. The cost-effectiveness of increasing the maintenance dose in
SMART is not established. METHODS: In this post hoc
hypothesis-generating analysis, data from two 6-month double-
blind trials of similar design, performed in moderate/severe
asthma populations (mean baseline data: FEV1 70–72% pre-
dicted, ICS 705–740 mg/d), examined the cost-effectiveness of
preventing exacerbations and reducing the percent of uncon-
trolled patients (Asthma Control Questionnaire score1.5) with
B/F 160/4.5 mg bid + prn (Study 1; Kuna et al. Int J Clin Pract
2007) and B/F 2 ¥ 160/4.5 mg bid + prn (Study 2; Bousquet et al.
Respir Med 2007) using 2008 Spanish health care costs. Incre-
mental cost-effectiveness ratios were estimated. RESULTS: The
analysis included 2173 SMART-treated patients. There were 12
exacerbations/100 patients/6 months in each study, and patients
uncontrolled on SMART decreased from 66% to 30% and 62%
to 23% in Study 1 and 2, respectively. Total health care costs
during 6-months of therapy were €366 and €512/patient, respec-
tively. The incremental cost of preventing 3 extra patients in
100 having uncontrolled asthma with high- vs low-dose SMART
was estimated at €4867/patient. CONCLUSIONS: Low-dose
SMART appears to provide unsurpassed exacerbation control
at a low cost but high-dose SMART may achieve better clinical
control in a small minority of patients. These ﬁndings will be
investigated prospectively in >8000 patients in a 6-month study
(EuroSMART) to establish the cost and proﬁle of patients
needing high-dose SMART.
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COST-EFFECTIVENESS ANALYSIS OF SYMBICORT SMART®
VERSUS FIXED COMBINATIONTREATMENTS IN FINLAND
Tamminen K1, Laine J1, Soini EJ2, Martikainen JA2, Kankaanranta H3
1AstraZeneca, Espoo, Finland, 2ESiOR Oy, Kuopio, Finland, 3Seinäjoki
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OBJECTIVES: To explore the short-term cost effectiveness of
Symbicort SMART (using Symbicort Turbuhaler) as compared
with ﬁxed combination therapies (budesonide/formoterol and
salmeterol/ﬂuticasone) with terbutaline as needed in the treatment
of asthma. METHODS: Within the clinical trial economic analy-
sis, Finnish unit costs applied to pooled resource use data and
multinomial cost-effectiveness acceptability curves were formed
based on bootstrapping. RESULTS: Use of Symbicort SMART
signiﬁcantly reduced the rate of severe asthma exacerbations as
compared with ﬁxed dose combinations. The total costs over 6
months were €475 per patient for those who used the Symbicort
SMART treatmentmodel, whichwas €99–107 lower than the cost
of ﬁxed dose combinations. Symbicort SMART treatment model
achieved a very high probability (98.3%) of cost effectiveness.
CONCLUSIONS: Symbicort SMART treatment model should be
considered in the treatment of moderate to severe asthma instead
of conventional treatment with combination products in view
of its good clinical efﬁcacy and a very high probability of cost
effectiveness in the Finnish setting.
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